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Protein-protein interactions play a central role in
medicine, and their modulation with small organic
compounds remains an enormous challenge.
Because it has been noted that the macromolecular
complexes modulated to date have a relatively pro-
nounced binding cavity at the interface, we decided
to perform screening experiments over the vascular
endothelial growth factor receptor (VEGFR), a vali-
dated target for antiangiogenic treatments with a
very flat interface. We focused the study on the
VEGFR-1 D2 domain, and 20 active compounds
were identified. These small compounds contained
a (3-carboxy-2-ureido)thiophen unit and had IC50
values in the low micromolar range. The most potent
compound inhibited the VEGF-induced VEGFR-1
transduction pathways. Our findings suggest that
our best hit may be a promising scaffold to probe
this macromolecular complex and for the develop-
ment of treatments of VEGFR-1-dependent diseases.
INTRODUCTION
Protein-protein interactions (PPIs) are pervasive in biology but
are classically challenging targets. The human interactome is
predicted to include about 650,000 interactions (Stumpf et al.,
2008), among which a sizeable number could be modulated by
low molecular weight compounds (Wells and McClendon,
2007). Several conceptual and technical hurdles to the efficient
targeting of PPIs have been proposed, including the nature of
the chemicals present in the compound collections, the plasticity
of the interfaces, and access to a relevant in vitro assay (Speran-
dio et al., 2010b). Furthermore, interfaces are usually large (anChemistry & Biology 18, 1631–163average interface area of 1,000–2,000 A˚2 is often observed for
heterodimeric protein-protein complexes) and flat and have
generally not evolved to bind low molecular weight molecules
(Higueruelo et al., 2009). Recent successes in the field pave
theway for a paradigm shift in drug discovery and basic research
(Fry, 2008; Villoutreix et al., 2008; Wells and McClendon, 2007),
although it has been pointed out that the macromolecular
complexes modulated to date essentially lie toward the more
druggable end of the PPI difficulty spectrum (Arkin and Whitty,
2009). One would expect that a protein complex easier to screen
most likely has a relatively pronounced cavity at the interface,
facilitating the binding of a small molecule. Indeed, the planarity
(root-mean-square deviation of all the interface atoms from the
least square plane through the atoms) values of most protein-
protein complexes successfully inhibited by small molecules
tend to be between 2.3 and 3.6 A˚ (the smaller is the planarity
index; the flatter is the surface) (Reynolds et al., 2009), indicating
the presence of a relatively deep binding groove (Figure S1 avail-
able online). Yet, some very flat interfaces inhibited by a small
drug-like molecule have been reported, like, for instance, for
the X-linked inhibitor of apoptosis (XIAP), which has a planarity
value of 1.8 A˚ (Arkin and Whitty, 2009; Fry, 2008).
We, thus, decided to revisit several therapeutically important
protein-protein interfaces with known three-dimensional (3D)
structures. We found that the vascular endothelial growth factor
receptor (VEGFR), a protein that binds to the vascular endothelial
growth factor (VEGF), had a planarity value of 1.7 A˚, well below
those of most transient protein-protein complexes (mean pla-
narity value = 2.7 A˚; Reynolds et al., 2009). In addition, VEGFR
plays a key role in angiogenesis, one of the hallmarks of cancer
(Ferrara and Kerbel, 2005; Hanahan andWeinberg, 2000; Hicklin
and Ellis, 2005). VEGF binds to two major tyrosine kinase recep-
tors (TKRs), VEGFR-1 and VEGFR-2, on the surface of endothe-
lial cells, thereby activating signal transduction and regulating
both physiological and pathological angiogenesis. Whereas
VEGFR-1 has been shown to stimulate endothelial cell migration9, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1631
Figure 1. The VEGF-VEGFR-1 Complex
Schematic diagram illustrating our approach for blocking VEGF signaling by
inhibition of VEGF-VEGFR PPI. The approach followed in this work does not
intend to inhibit the tyrosine kinase site but aims at the inhibition of a PPI (red
arrows) through design of a ligand binding to the D2 domain by combining
in silico-in vitro screening experiments. See also Figure S1.
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Inhibition of the VEGF-VEGFR Interaction(Kanno et al., 2000; Ziche et al., 1997), VEGFR-2 is known to be
the main mediator of signaling pathway in endothelial cells
(Holmes et al., 2007; Olsson et al., 2006).
Both VEGFR molecules have an extracellular component
containing seven immunoglobulin-like domains (extracellular
domains [ECDs], D1–D7), a single transmembrane segment,
and an intracellular domain with a consensus tyrosine kinase
sequence (Shibuya et al., 1990; Terman et al., 1991) (Figure 1).
The VEGF-VEGFR interaction or the catalytic activity of the
VEGFR is currently targeted by drugs such as bevacizumab
(antibody), sunitinib, and sorafenib (tyrosine kinase inhibitors),
whereas the soluble receptor (aflibercept) is currently in clinical
trials (Grothey and Galanis, 2009; Ivy et al., 2009; Ja¨nne et al.,
2009). These drugs are, thus, either injected proteins such as
bevacizumab (Avastin) targeting VEGF itself and are not orally
active or oral tyrosine kinase inhibitors but are not specific for
VEGFR. A small molecule orally available inhibiting the VEGF-
VEGFR interaction could, therefore, be of interest as compared
to therapeutic proteins because the cost of the treatment should
be significantly lower and more convenient to the patient and
medical team. The concept has in fact been validated using
small peptides (D’Andrea et al., 2005; Gautier et al., 2010; Gon-
calves et al., 2007a; Jia et al., 2001; Zilberberg et al., 2003) and1632 Chemistry & Biology 18, 1631–1639, December 23, 2011 ª2011nondrug-like organicmolecules (Ueda et al., 2004a, 2004b), sup-
porting further the rationale of our study.
The overall process to investigate the VEGF-VEGFR complex
is illustrated in Figures 1 and 2. We analyzed the surface of the
receptor and used structure-based virtual ligand screening
(SB-VLS) (Sperandio et al., 2006) to identify drug-like competi-
tive antagonists of the VEGF-VEGFR-1 complex. We identified
one series of chemicals able to inhibit the flat VEGF-VEGFR-1
interaction and, subsequently, focused our attention on the
most potent compound of this series, molecule 4321 (Table S1).
This compound was investigated by NMR and in cellular assays
and was found to inhibit the VEGF165 (a 165 amino acid isoform
of VEGF)-induced VEGFR-1 phosphorylation and endothelial
cell tubulogenesis, highlighting its role as a newpromising antian-
giogenic agent. In addition this molecule was not found to
be toxic in WST-1 cell proliferation assays, consistent with its
in silico absorption, distribution, metabolism, excretion, and
toxicity (ADMET) profile (Table S2).
RESULTS AND DISCUSSION
Binding Pocket Prediction and In Silico Screening
We investigated the crystal structure of the VEGFR-1 D2 domain
and carried out a theoretical prediction of possible druggable
pockets within and around the experimental protein-protein
binding zone. Not only part of the region interacting with VEGF
but also subpockets some distance away from this interfacial
area were predicted as potentially interesting for docking exper-
iments. However, the surface topology around the binding site of
the VEGF on the VEGFR-1 is flat and large (>800 A2), suggesting
that SB-VLS computations could be challenging. We identified
three interesting small subpockets with the Surflex-Protomol
probe-mapping algorithm (CH4, C = O, and N-H groups were
used to search for areas capable of interacting favorably with
an incoming ligand) (Jain, 2003) and through interactive struc-
tural analysis (Figure 2). We also took into account the results
of previously reported mutagenesis studies, which showed that
the K16, F17, M18, Y21, Q22, and Y25 amino acid residues of
the VEGF N-terminal a helix were potentially important for inter-
actions with VEGFR (Fuh et al., 2006; Keyt et al., 1996; Li et al.,
2000; Muller et al., 1997; Pan et al., 2002). Our analysis high-
lighted a polar subpocket A, formed by residues K170, T206,
E208, and K217, a region in contact with the VEGF residue
Q22. Subpocket A overlaps only partially with the direct
protein-protein interface, but it forms a small crevice within
which a small compound could be anchored in this otherwise
flat region. Subpocket B consists essentially of hydrophobic/
aromatic residues (e.g., of residues Y139, I142, P143, N219,
L221) and is in contact with F17 andM18 of the VEGF N-terminal
a helix. Two tyrosine groups, Y21 and Y25 of the VEGF a helix,
interact with the essentially hydrophobic and planar subpocket
C (e.g., of residues Y199, K171, F172, P173, L204). We investi-
gated the overall nature of this region further by identifying key
interaction sites with another probe-mapping method (probes =
positively charged sp3 nitrogen, a negatively charged sp2 oxy-
gen, and a sp3 carbon) as implemented in LigBuilder (Wang
et al., 2000), in which only the strongest interacting groups
survive at the surface. Only seven carbon probes remained,
mostly located in subpockets B and C, further highlighting theElsevier Ltd All rights reserved
Figure 2. Structural Analysis of the VEGF-VEGFR-1
Complex
Left view shows the crystal structure (Wiesmann et al.,
1997) of residues 8–109 of VEGF (VEGF8–109 cartoon
diagram) in complex with VEGFR-1 D2 domain (shown
here in solid-surface representation: yellow, hydrophobic/
aromatic; red, oxygen atom and/or negatively charged;
blue, nitrogen atom and/or positively charged). A probe-
mapping algorithm (Jain, 2003) was used to analyze the
interface area (green sphere highlights regions where
carbon atoms can bind with reasonable affinity, blue
spheres represent nitrogen atoms, and red spheres,
carbonyl groups). Three subpockets, A, B, and C, could be
identified and are shown as dashed circles.
Right-top dashed square illustrates the deformability in
the screening region that was assessed with the DFprot
server (Garzon et al., 2007). Color-coded deformation
values are projected on a mesh representation of the
receptor. In the screening region, areas of Y139 and F172
are expected to be flexible (deformable regions are in red;
regions somewhat more flexible are in light blue and
green), whereas the interface itself, color coded in dark
blue, appears relatively rigid.
Right-bottom dashed square shows the overall search
zone investigated during the docking computations that is
delineated by the dashed lines and forms a relatively large
triangle.
See also Figure S2.
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Inhibition of the VEGF-VEGFR Interactionoverall hydrophobic nature of this region. Receptor flexibility
is known to be important in some biological systems, and
normal mode analysis (NMA) is an efficient method for investi-
gating this property (Cavasotto et al., 2005; Sperandio et al.,
2010a). We, thus, carried out NMA on our biological target
using the DFprot server, a structural bioinformatic tool that
predicts protein deformability starting from a single-input 3D
structure (Garzo´n et al., 2007). Areas of VEGFR-1 residues
Y139 and F172 were predicted to be slightly flexible, whereas
the direct interface with VEGF appeared rigid (Figure 2). The
computed deformability is consistent with the B factors of the
crystal structure of VEGFR-1 and with the NMR structures of
VEGFR-1 (Starovasnik et al., 1999). These results suggest
that it is acceptable to maintain the target rigid during the
docking computations assuming that the algorithm is not too
sensitive to tight atomic contacts and that the redocking of
some compounds would benefit from the use of a method
capable of handling the flexibility of some amino acid side
chains.
The 8,000 chemical compounds of the Centre d’Etudes et de
Recherche sur le Me´dicament de Normandie (CERMN) library
were then docked with Surflex onto the defined target zones,
and the predicted binding affinities were initially estimated for
each pose with the default scoring function. Because a few resi-
dues in this region are predicted to be flexible, we thought that it
would be appropriate to take flexibility into account implicitly by
tuning the ‘‘penetration’’ parameter of Surflex (please refer to ‘‘In
Silico Procedures’’ in the Supplemental Experimental Proce-
dures). The docked compounds were reranked during a post-
processing step, with a pocket-tuned scoring function (Miteva
et al., 2005a). We selected an initial list of 350 molecules after
a visual inspection of the top-ranked 2,500 compounds. These
molecules were then analyzed with our rule-based ADMET-
filtering package (Lagorce et al., 2008, 2011) and by medicinalChemistry & Biology 18, 1631–163chemists. This process led to the selection of a final list of 206
compounds for experimental testing.
Predicted Modes of Binding for the Best Inhibitor
To investigate the likely binding mode of our best inhibitor,
compound 4321 (see below), we analyzed different binding
poses in the three predicted subpockets A, B, and C (Figure S2).
Although the targeted zone is mostly hydrophobic, three or four
hydrogen bonds could potentially form between the VEGFR-1
D2 domain and compound 4321. Additional analyses were
then carried out with AutoDock4 (Morris et al., 2009) but this
time by allowing explicit flexibility of several amino acid side
chains. We found that compound 4321 is most likely binding to
subpockets B and C (the three lowest energy positions).
In Vitro VEGF Displacement Assays and the Inhibitors
Identified
Weassessed thebindingof the 206selected small compounds to
VEGFR-1 by a chemiluminescence assay based on competition
with biotinylated VEGF165 (btVEGF165) for binding to the ECDs
of VEGFR-1 (VEGFR-1 D1–D7) (Goncalves et al., 2007b) (please
refer to ‘‘Biological Reagents’’ in the Supplemental Experimental
Procedures). Given the challenging topology of the interface, we
initially tested the compounds at a relatively high concentration
of 200 mM, at which 33 compounds displayed 21%–100% inhibi-
tion. Of these compounds, 6 gave 41%–60% inhibition, 16 gave
61%–80% inhibition, and11gave81%–100%inhibition.Wecon-
sidered molecules giving more than 60% inhibition at 200 mM to
be most promising. This criterion identified 20 hits from 1 chem-
ical family (the (3-carboxy-2-ureido)thiophen series; Figure 3;
Table S1). These 20 molecules inhibited the formation of the
VEGF165-VEGFR-1 complex with IC50 values of 135–18 mM
(Table S1) and appeared to be interesting from a structural,
pharmacokinetic, and toxicological standpoint (Table S2).9, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1633
Figure 3. General Structure of the (3-Carboxy-2-Ureido)Thiophen
Series
In Compound 4321: R1, Ethyl; R10, Benzyl. See also Figure S3, and Tables S1
and S2.
Figure 4. WaterLOGSY Experiments
Structure of the compound 4321, 1D spectra, andWaterLOGSY spectra of the
compound in the absence of the VEGFR-1 D2 (A and C) and in the presence of
the domain VEGFR-1 D2 (B and D). The positive signal of the compound on
spectra D demonstrates an interaction between the small molecule and the
VEGFR-1 D2. Some peaks arising from VEGFR-1 D2 are visible, in particular in
the 1D spectra (B) around 3 ppm.
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Inhibition of the VEGF-VEGFR InteractionOne compound, molecule 4321, competed with btVEGF165 for
binding to the ECDs of VEGFR-1 (D1–D7, noted VEGFR-1 ECD)
with an IC50 value of 18 mM. Ruch et al. (2007) recently showed
that VEGF binding to VEGFR-2 induced conformational changes
of the receptors, leading to receptor dimerization and intracel-
lular tyrosine kinase activation. These changes result from
homotypic interactions between the immunoglobulin-like do-
mains 4 (Barleon et al., 1997) and 7 of the monomers (Ruch
et al., 2007). These data suggest that compounds targeting the
D4 or D7 domains may act as VEGFR-1 antagonists, preventing
dimerization. To rule out this mechanism, we assessed the ability
of our compounds to displace the interaction between the
VEGFR-1 D1–D3 domains and VEGF. Here, compound 4321
had an IC50 value of 10 mM, giving a ligand efficiency of about
0.32 kcal mol1 per nonhydrogen atom (the maximum possible
value is about 1.5 kcal mol1), equivalent to those of many kinase
and protease inhibitors (Wells andMcClendon, 2007). The result-
ing displacement curves of both tests are available in Figure S3.
WaterLOGSY Experiments
Several NMR experiments have been designed to characterize
the interaction between a ligand and its target protein, such as
saturation transfer difference (Mayer and Meyer, 1999), reverse
NOE pumping (Chen and Shapiro, 2000), transferred NOE
(Meyer et al., 1997), and more recently, the Water-Ligand Ob-
served via Gradient SpectroscopY (WaterLOGSY) experiments
(Dalvit et al., 2001). The WaterLOGSY seems to have the higher
sensitivity compared to other methods, and we applied this
approach to demonstrate that compound 4321 binds to
VEGFR-1 D2 and not to VEGF. With this approach it is possible
to discriminate between binding and nonbinding ligands accord-
ing their signal on the NMR spectra.1634 Chemistry & Biology 18, 1631–1639, December 23, 2011 ª2011Figure 4 shows the 1D spectra and the WaterLOGSY of the
compound 4321 in the absence of the VEGFR-1 D2 (Figures
4A and 4C) and in the presence of the protein (Figures 4B
and 4D). The WaterLOGSY of the free compound (Figure 4C)
contains several peaks of different intensity with different
signals. Protons from molecule 4321 are easily identified, and
three extra-broad resonances arising from a quaternary ammo-
nium are observed around 7 ppm. These three last peaks arise
from an exchange with water, they are not observed on the basic
1D spectra, and they give a signal of opposite sign in the
WaterLOGSY. In the presence of the protein VEGFR-1 D2
(Figure 4C), an inversion of the sign of the resonances from
4321 occurs. The inversion of the signal of 4321 in the Water-
LOGSY spectra in presence of the protein is characteristic of
its interaction with the protein because as the ligand adopts
the tumbling correlation time of the protein, its signal is inverted
on the spectra because of the negative NOE.
Compound 4321 Specifically Inhibits the
VEGF165-Dependent Phosphorylation of VEGFR-1
We analyzed both the biochemical effect and the specificity of
compound 4321 by assessing its ability to inhibit the VEGF165-
induced autophosphorylation of VEGFR-1 and VEGFR-2 (please
refer to ‘‘Biological Results’’ in the Supplemental ExperimentalElsevier Ltd All rights reserved
Figure 5. Compound 4321 Inhibits VEGF-
Induced Phosphorylation of Both VEGFR-1
and VEGFR-2
Starved HUVECs were incubated with compound
4321 at the indicated concentration over a period
of 1 hr and then stimulated by VEGF165 50 ng/ml
during 5 min, cells were lysed, and cellular
extracts were submitted to specific antibodies.
Western blots were performed with anti-phospho-
VEGFR-1 (P-VEGFR-1) and anti-VEGFR-1 (A) and
anti-phospho-VEGFR-2 (P-VEGFR-2) and anti-
VEGFR-2 (B), and in both cases anti-a-tubulin was
used as control (data result from three indepen-
dent experiments). Relative optical density of
the bands in arbitrary units is represented for
P-VEGFR-1 (C) and P-VEGFR-2 (D) both reported
to the a-tubulin control. All results are expressed
asmean ± SD. Control without VEGF is considered
as 100%. *p < 0.0001 versus the group without
VEGF165; **p < 0.0001 and ***p < 0.001 versus the
group with VEGF165.
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Inhibition of the VEGF-VEGFR InteractionProcedures). HUVE cells (HUVECs), a widely used model for
angiogenesis, were chosen for this study. Compound 4321
clearly inhibited VEGFR-1 phosphorylation at concentrations
between 1 and 100 mM (Figure 5A and corresponding quantiza-
tion in Figure 5C), whereas VEGFR-2 phosphorylation was
partially inhibited only at 100 mM (Figures 5B and 5D). Thus,
compound 4321 seems to decrease the phosphorylation of
VEGFR-1 more efficiently than that of VEGFR-2.
Compound 4321 Inhibits the VEGF-Induced Formation
of Tubule-like Structures in HUVECs
It has been shown that the induction of branching morphogen-
esis in HUVECs is dependent on VEGFRs. In a 3D Matrigel
medium, mimicking the basal membrane, HUVECs branch to
form tubule-like structures. This process mimics the endothelial
tubulogenesis that occurs during the formation of new vessels.
Once HUVECs were seeded on Matrigel, VEGF stimulation
(50 ng/ml) induced a capillary tube network composed of cells
that migrated and extended to join themselves (Figure 6A,
VEGF alone). The negative control without VEGF (Figure 6A,
No VEGF) displayed no structured capillary tube drafts. The
treatment of HUVECs with molecule 4321 clearly inhibited the
VEGF165-induced endothelial cell tubulogenesis. Indeed, this
molecule decreased the number of branching junctions formed
by HUVECs on Matrigel in a dose-dependent manner (from 1
to 100 mM; quantization in Figure 6B), with no capillary tube
formation; as for the negative control, when compound 4321
was used at concentrations of 100, 33, and 10 mM. Interestingly,
in tests at a concentration of 10 mM, this molecule displayed no
toxicity in WST-1 colorimetric tests on HUVECs.
These data confirm that 4321 compound preferentially tar-
geted the VEGR-1 receptor. Moreover, the branching morpho-
genesis of HUVECs has been shown to be due to both migration
and cell differentiation. Cell migration is a complex phenomenon
that requires cytoskeleton-regulated cell motility and cell adhe-
sion. Lauffenburger and Horwitz (1996) and Kanno et al. (2000)
have shown that VEGFR-1 regulates cell migration through the
modulation of actin reorganization. We, therefore, investigatedChemistry & Biology 18, 1631–163the effect of compound 4321 on actin and tubulin organization.
We chose to use a dose of only 10 mM for compound 4321. At
this concentration, this compound inhibited the phosphorylation
of VEGFR-1, but not that of VEGFR-2 (Figure 5), and tube forma-
tion by HUVECs (Figure 6). Immunofluorescence experiments
were then carried out with anti-actin and anti-tubulin antibodies
(Figure S4). The stimulation of cells with 50 ng/ml VEGF elicited
the reorganization of both the actin and tubulin networks. This
phenomenon was clearly inhibited by 10 mM 4321. Indeed,
compound 4321 induced an effect similar to that induced by a
specific and previously reported anti-VEGFR-1 antibody (Kanno
et al., 2000). These results support the hypothesis that com-
pound 4321 targets VEGFR-1.
SIGNIFICANCE
Common characteristics of protein-protein interfaces that
have been inhibited by a small molecule were the presence
of either a relatively deep binding groove or of several small
subpockets (Fuller et al., 2009). In our case, although the
VEGF-VEGFR-1 interface is very flat, we could find three
subpockets. We performed a conformational search and
docking computations over a large area that extended out-
side the direct protein-protein interface. The success of
the in silico screening on this flat surface could be due to
both the presence of small cavities and the overall rigidity
of the region. Furthermore, it would be interesting to explore
if the size and physicochemical nature of the compounds
could play a role in addressing flat interfaces.
Overall, we have identified 20 compounds disrupting one
of the flattest known therapeutically important protein-
protein interfaces (hit rate, 9.7%). To the best of our knowl-
edge, our best inhibitor is the first drug-like molecule
discovered by structure-based screening to inhibit specifi-
cally the formation of the VEGFR-1-VEGF complex. This
inhibitor is easy to synthesize, is smaller (molecular mass,
304 kDa) thanmany previously reported PPI inhibitors (Sper-
andio et al., 2010b), and has a reasonable ligand efficiency9, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1635
Figure 6. Effect of Compound 4321 on Tubule Formation Network
(A) HUVECs were seeded on Matrigel with or without 50 ng/ml of VEGF165 in the presence or the absence of compound 4321 at the indicated concentrations.
Tube-like structures were visualized 4 hr later.
(B) Tube-like structures formation was quantified by the number of branching points. The control without VEGF165 is considered as 100%, and results are
expressed as the mean ± SD. *p < 0.0001 versus the group without VEGF165; **p < 0.0001 versus the group with VEGF165.
See Figure S4.
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Inhibition of the VEGF-VEGFR Interaction(0.32 kcal mol–1 per nonhydrogen atom). Many recent publi-
cations have described the role of VEGFR-1 in cancers such
as breast cancer, acute myeloid leukemias, and acute
lymphoblastic leukemia (Dales et al., 2003; Fragoso et al.,
2006; Hiratsuka et al., 2001, 2002; Kracmarova et al., 2008;
Luttun et al., 2004; Stefanik et al., 2001). Our best molecule,
4321, prevented VEGFR-1 signaling pathway and is more
specific for VEGFR-1 than VEGFR-2. Thus, molecule 4321
constitutes a potent pharmacological probe for studies of
cancer and other angiogenesis-driven disorders, and our
results support the idea of developing PPI inhibitors even
for flat interfaces.
EXPERIMENTAL PROCEDURES
The CERMN Compound Collection
The CERMN-Normandy Drug Study and Research Center (http://www.cermn.
unicaen.fr/) collection is part of the French compound library initiative and
contains over 8,000 original molecules that have been synthesized for drug
discovery projects (Hibert, 2009).
Target and Compound Preparation and In Silico Screening Protocol
The structure of the VEGFR-1 protein target was obtained from the X-ray struc-
ture of the VEGF-VEFGR-1 D2 complex (PDB ID: 1FLT, resolution 1.70 A). For
VEGFR-1 the protonation states of residues were assigned at pH 7.0, after
computations with the Protein Continuum Electrostatic server (Miteva et al.,
2005b). Binding pocket predictions were carried out with two probe-mapping
methods: LigBuilder (Wang et al., 2000) and Surflex (Jain, 2003). All 8,000
molecules of the CERNM collection were docked. We generated a single 3D
conformer for eachmolecule with our in-house programDG-AMMOS (Lagorce
et al., 2009). The top 2,500 docked poses, with the best Surflex scores
(between 7.67 and 4.60), were analyzed with PyMOL (DeLano, San Carlos,
CA), and 350 molecules were selected. Additional docking experiments of
the best compound, molecule 4321, were performed with AutoDock4 (Morris
et al., 2009) with some side chains in the binding area allowed to be flexible1636 Chemistry & Biology 18, 1631–1639, December 23, 2011 ª2011during the docking runs (see Supplemental Experimental Procedures for
detailed explanations).
HUVEC Culture
HUVECs were cultured in EGM-2 at 37C, in a humidified atmosphere contain-
ing 5% CO2 in air, and the medium was changed every 2 days. HUVECs were
used for experiments from the second to the fifth passage.
In Vitro VEGFR-1 Chemiluminescent Assay
The assay was performed as previously described (Goncalves et al., 2008).
Briefly, a fixed amount of biotinylated human VEGF165 (131 pM) was incubated
with the screened compounds in a 96-well microplate coated with a human
VEGFR-1 ECD/Fc chimera or a VEGFR-1 D1–D3 domains/Fc chimera. The
residual btVEGF165 present after washing was detected by chemiluminescent
with horseradish peroxidase-conjugated streptavidin.
Western Blot Analysis
The western blot experiments were performed as previously described (Gon-
calves et al., 2008), but with some modifications. Confluent HUVECs in 6-well
plates were starved by incubation overnight in EBM-2 without supplements.
HUVECs were incubated with compounds for 1 hr, at the indicated concentra-
tions, and were then stimulated with 50 ng/ml (131 nM) VEGF165 for 5 min.
HUVECs were lysed in 1% NP40 plus 1% Bridj 96 lysis buffer. The lysate
was subjected to SDS-PAGE in an 8% polyacrylamide gel, and the resulting
bands were transferred onto nitrocellulose membranes. The membranes
were incubated with the indicated antibodies at a dilution of 1:1,000, with
the exception of the anti-tubulin antibody, which was used at a dilution of
1:20,000. Antibody binding was detected by enhanced chemiluminescence
with a CCD camera (Fisher Bioblock Scientific, Illkirch, France), and densitom-
etry analysis was performed with Chemicapt 3000 software (Fisher Bioblock
Scientific). The results are expressed assuming a value of 100% for the
untreated wells.
Formation of Tubule-like Structures
We added 75 ml of Matrigel containing only low levels of growth factors to
a 96-well microplate and allowed polymerization to occur at 37C for
30 min. Confluent HUVECs were cultured overnight in EBM-2 withoutElsevier Ltd All rights reserved
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Inhibition of the VEGF-VEGFR Interactionsupplements or FBS, and the cells (23 104) were then used to seed wells con-
taining EBM-2 alone or supplemented with 50 ng/ml (1.3 nM) VEGF165, in the
presence or absence of various compounds at the concentrations indicated.
Four hours later, the endothelial cell-derived tube-like structures were visual-
ized under an inverted microscope and photographed at a magnification of
320. The formation of tube-like structures was quantified by calculating the
number of branching points with ImageJ software. Results are expressed
assuming a value of 100% for untreated cells.
Expression, Purification, and Folding of VEGFR-1 D2
The VEGFR-1 D2 domain (residues 133–225) was cloned into the pet22
expression vector (Novagen) and transformed in E. coli Rosetta-gami (DE3)
pLysS bacterial strain (Novagen). Cultures were grown at 37C in LB supple-
mented with 150 mg/l ampicillin. When the cell density reached an OD of 0.4
at 600 nm, protein expression was induced by the addition of 0.4mM isopropyl
b-D-1-thiogalactopyranoside. VEGFR-1 D2 was expressed as insoluble pro-
tein. After 4 hr, cells were harvested by centrifugation and resuspended in
Tris/HEPES buffer (50 mM/50 mM [pH 8.1]) containing 1% (W/V) Triton
X-100. Cells were lysed by ultrasonic disruption. Inclusion bodieswere isolated
by centrifugation at 9,5003 gduring 20min at 4C. The pellet was submitted to
this treatment (resuspension, sonication, centrifugation) three additional times.
Dried pellet (0.625 g) was suspended by sonication in 1 ml Tris/HEPES 50 mM
(pH 8.1), DTT 20 mM, then solubilized in 30 ml urea 8 M HEPES/NaOH 25 mM
(pH 6.8) (solution A [Sol. A]). Solubilized VEGFR-1 D2 was purified by cation-
exchange chromatography on a source 15 S column (Amersham) previously
equilibrated with Sol. A, and eluted by Sol. A plus NaCl 1 M. Unfolded D2 puri-
fied in urea reached 190 mg for 1 liter of E. coli culture.
Refolding was performed as follows. Solubilized VEGFR-1 D2 (0.5 mg/ml)
was dialyzed overnight against 20 vol HEPES 25 mM (pH 6.8) at 4C. Dialysis
was repeated once in the same conditions. A total of 600 mM (NH4)2SO4
was then added to precipitate misfolded protein. Insoluble material was
isolated by centrifugation at 9,500 3 g during 15 min at 4C and recycled by
solubilization in Sol. A without further reduction. It was refolded following the
same protocol. This was repeated several times leading to a final refolding
rate of 70%. Soluble refolding products were further purified on a Phenyl
Sepharose column (Amersham) equilibrated with HEPES/NaOH 25 mM
(pH 6.8) plus 600 mM (NH4)2SO4 and eluted by a linear gradient of HEPES/
NaOH 25 mM (pH 6.8). Typical results are 70 mg of folded and purified
VEGFR-1 D2 for 1 liter of initial cell culture. The protein was lyophilized for
long-range storage.
NMR Experiments
All NMR spectra were recorded at 293 K on a 600 MHz Bruker Avance spec-
trometer equipped with a 5 mm triple resonance inverse probe and an xyz
gradient unit. A 1D 1H-NMR reference spectrum was recorded for compound
4321 in the presence and the absence of the protein VEGFR-1 D2. The
small molecule was prepared at a concentration of 500 mM, and the protein
VEGFR-1 D2 was added at the concentration of 25 mM in H2O/D20 (90/10).
DMSO-d6 (5%) was added to solubilize the compound in H2O.Water suppres-
sion was achieved by using excitation sculpting with gradient sequence
(Hwang and Shaka, 1995). WaterLOGSY NMR experiments (Dalvit et al.,
2001) used a 5 ms selective Gaussian 180 pulse at the water signal frequency
and a 1.1 s NOE mixing time. The spectra were recorded with a spectral width
of 6009 Hz, a 3 s relaxation delay, 128 scans for the 1D reference spectra, and
1 or 3 k scans for the WaterLOGSY spectra.
Statistical Analysis
For IC50 determination, each experimentwas performed three times in triplicate.
Thedataareexpressedasmeanof the threeexperimentsand thecorresponding
SD. For biological experiments the statistically significant differences between
the groups were determined via a two-way ANOVA followed by the Student’s t
test, in GraphPad Prism 3. Values of p <0.05 were considered significant.
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